{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:50:41Z","timestamp":1792461041320,"version":"4.5.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are recommended for reducing the renal and cardiovascular risk in patients with chronic kidney disease (CKD) based on the positive results reported by clinical trials. However, real-world data on the efficacy and the safety of these drugs in CKD population followed in nephrology setting are lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We report the effects of dapagliflozin in CKD patients by using data collected during a learning program in which 105 nephrologists added dapagliflozin (10\u00a0mg\/day) to consecutive patients referred to their renal clinics. Efficacy endpoints were the albuminuria change and the determinants of an albuminuria decline \u226530%. Adverse events were also collected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 1724 patients with CKD (age 67.4\u00a0\u00b1\u00a013.2 years, 72.8% males, diabetes 59.9%, eGFR 43.5\u00a0\u00b1\u00a017.4\u00a0ml\/min\/1.73 m2, severe albuminuria 70.1%) received dapagliflozin for 4\u00a0\u00b1\u00a01 months. Dapagliflozin significantly reduced body weight (\u22121.3\u00a0kg), eGFR (\u22120.27\u00a0ml\/min\/month), and blood pressure (\u22123.6\/\u22121.7\u00a0mmHg). Albuminuria declined by 25.1% (95%CI 23.0\u201327.2) from 500\u00a0mg\/day [IQR 225\u20131425] to 320\u00a0mg\/day [IQR 100\u2013900]. Albuminuria reduction was \u226530% in 48.3% of patients, 0\u201329% in 37.6% while it increased in 14.1% of patients. At logistic regression analysis, older age, female sex, use of mineralocorticoid receptor antagonist, higher eGFR, and higher albuminuria were all significant predictors of albuminuria decline \u226530%. We collected 46 side effects leading to drug discontinuation in 36 patients (2%), with acute kidney injury and urinary tract infection being the most frequent adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We provide evidence of the anti-proteinuric efficacy of short-term dapagliflozin in the presence of good safety profile in patients with CKD followed in nephrology.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfae396","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T18:02:16Z","timestamp":1733853736000},"source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of dapagliflozin in patients with CKD: real-world experience in 93 Italian renal clinics"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5686-2089","authenticated-orcid":false,"given":"Roberto","family":"Minutolo","sequence":"first","affiliation":[{"name":"Nephrology and Dialysis Unit, Department of Advanced Medical and Surgical Sciences, University of Campania , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Borrelli","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Department of Advanced Medical and Surgical Sciences, University of Campania , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ambrosini","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit , ASST dei Sette Laghi, Varese ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Amoroso","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, \u201cG. Mazzini\u201d Hospital , Teramo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1027-7049","authenticated-orcid":false,"given":"Filippo","family":"Aucella","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit , Casa Sollievo della Sofferenza Foundation, San Giovanni Rotondo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Batini","sequence":"additional","affiliation":[{"name":"Nephrology Unit ASL Toscana NordOvest , Livorno ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Battaglia","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Verona , Verona ,","place":["Italy"]},{"name":"Nephrology and Dialysis Unit, Pederzoli Hospital , Peschiera del Garda ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bregoli","sequence":"additional","affiliation":[{"name":"Nephrology Unit , ASST Spedali Civili Brescia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cantaluppi","sequence":"additional","affiliation":[{"name":"Nephrology and Kidney Transplantation Unit, Department of Translational Medicine (DIMET), University of Piemonte Orientale (UPO), \u201cMaggiore della Carit\u00e0\u201d University Hospital , Novara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cianciolo","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Kidney Transplant Unit , IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Conti","sequence":"additional","affiliation":[{"name":"Nephro-Urological Department , AUSL \u201cToscana Sud Est\u201d,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fabbrini","sequence":"additional","affiliation":[{"name":"Nephrology Unit, ASST Nord Milano , Ospedale Bassini, Cinisello Balsamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Giammarresi","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Kidney Transplant. Civico Hospital of Palermo , Palermo, \u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2656-5467","authenticated-orcid":false,"given":"Egidio","family":"Imbalzano","sequence":"additional","affiliation":[{"name":"Internal Medicine, Department of Clinical and Experimental Medicine, University of Messina , Messina ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"La Rosa","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, \u201cGiovanni Paolo II\u201d Hospital , Sciacca ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Marengo","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Department of Medical Specialties , ASLCN1, Cuneo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4018-0221","authenticated-orcid":false,"given":"Vincenzo","family":"Montinaro","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, \u201cMiulli\u201d General Hospital Acquaviva delle Fonti ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Musone","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine; Santa Maria Goretti Hospital , Latina ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4535-4182","authenticated-orcid":false,"given":"Marcello","family":"Napoli","sequence":"additional","affiliation":[{"name":"Nephrology Unit, Hospital V. Fazzi , Lecce,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Nappi","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Hospital Santa Maria della Piet\u00e0 , Nola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Pluvio","sequence":"additional","affiliation":[{"name":"Nephrology Unit, AORN dei Colli , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Santoro","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Department of Clinic and Experimental Medicine, University of Messina , Messina ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-0596","authenticated-orcid":false,"given":"Roberto","family":"Scarpioni","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, \u201cGuglielmo da Saliceto\u201d Hospital , Piacenza ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Sopranzi","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, County Hospital of Macerata , Macerata ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Tullio","sequence":"additional","affiliation":[{"name":"Nephrology Unit, Hospital A. Fiorini , Terracina ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8532-0182","authenticated-orcid":false,"given":"Luca","family":"De Nicola","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Department of Advanced Medical and Surgical Sciences, University of Campania , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"2025020409411137800_bib1","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2025020409411137800_bib2","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025020409411137800_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2025020409411137800_bib4","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"The Nuffield Department of Population Health Renal Studies Group and the SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet"},{"key":"2025020409411137800_bib5","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.xkme.2024.100851","article-title":"SGLT2 Inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health","volume":"6","author":"Madero","year":"2024","journal-title":"Kidney Med"},{"key":"2025020409411137800_bib6","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group","year":"2024","journal-title":"Kidney Int"},{"key":"2025020409411137800_bib7","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1111\/dom.15194","article-title":"Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020","volume":"25","author":"Nicholas","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025020409411137800_bib8","doi-asserted-by":"publisher","first-page":"E101","DOI":"10.9778\/cmajo.20210281","article-title":"Use of sodium-glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation","volume":"11","author":"Lau","year":"2023","journal-title":"CMAJ Open"},{"key":"2025020409411137800_bib9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.34067\/KID.0007862021","article-title":"Prescribing patterns of sodium-glucose cotransporter-2 inhibitors in patients with CKD: a cross-sectional registry analysis","volume-title":"Kidney360","author":"Zhuo","year":"2022"},{"key":"2025020409411137800_bib10","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.2337\/dc21-0529","article-title":"Prescribing trends of anti-diabetes medications in patients with type 2 diabetes and diabetic kidney disease, a cohort study","volume":"44","author":"Harris","year":"2021","journal-title":"Diabetes Care"},{"key":"2025020409411137800_bib11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12902-022-01026-2","article-title":"Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER","volume":"22","author":"Arnold","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"2025020409411137800_bib12","doi-asserted-by":"publisher","first-page":"e216139","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socio economic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025020409411137800_bib13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/dom.14874","article-title":"Ethnic and socio economic disparities in initiation of second-line antidiabetic treatment for people with type 2 diabetes in England: a cross-sectional study","volume":"25","author":"Bidulka","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025020409411137800_bib14","doi-asserted-by":"publisher","first-page":"E494","DOI":"10.9778\/cmajo.20220039","article-title":"Prescribing patterns and factors associated with sodium-glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease","volume":"11","author":"Ozaki","year":"2023","journal-title":"CMAJ Open"},{"key":"2025020409411137800_bib15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","article-title":"CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries","volume":"20","author":"Mosenzon","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2025020409411137800_bib16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12875-022-01731-w","article-title":"Under use of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study","volume":"23","author":"Hao","year":"2022","journal-title":"BMC Prim Care"},{"key":"2025020409411137800_bib17","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/ndt\/gfac276","article-title":"Generalizability of DAPA-CKD trial to the real-world setting of outpatient CKD clinics in Italy","volume":"37","author":"Minutolo","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2025020409411137800_bib18","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae071","article-title":"A comparison of sodium-glucose co-transporter 2 inhibitor kidney outcome trial participants with a real-world chronic kidney disease primary care population","volume-title":"Nephrol Dial Transplant","author":"Forbes","year":"2024"},{"key":"2025020409411137800_bib19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025020409411137800_bib20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial","volume":"12","author":"EMPA-KIDNEY Collaborative Group","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025020409411137800_bib21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a Scientific Workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025020409411137800_bib22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1001\/jama.2024.8914","article-title":"Sex differences in primary care-based chronic kidney disease management","volume":"332","author":"Rodriguez","year":"2024","journal-title":"JAMA"},{"key":"2025020409411137800_bib23","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1089\/jwh.2023.0059","article-title":"Sex-related disparities in prescription patterns of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and heart failure","volume":"32","author":"Hammer","year":"2023","journal-title":"J Womens Health"},{"key":"2025020409411137800_bib24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1053\/j.ajkd.2022.11.017","article-title":"Predictors, disparities, and facility-level variation: SGLT2 inhibitor prescription among US veterans with CKD","volume":"82","author":"Gregg","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2025020409411137800_bib25","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1681\/ASN.2022030373","article-title":"Sex differences in the recognition, monitoring, and management of CKD in health care: an observational cohort study","volume":"33","author":"Swartling","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025020409411137800_bib26","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.hfc.2022.03.002","article-title":"SGLT2 inhibitors and safety in older patients","volume":"18","author":"Pollack","year":"2022","journal-title":"Heart Fail Clin"},{"key":"2025020409411137800_bib27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-023-01743-5","article-title":"The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (\u2265\u200975 years): a retrospective, pharmacovigilance study","volume":"22","author":"Goldman","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2025020409411137800_bib28","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025020409411137800_bib29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s10157-015-1106-2","article-title":"Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial","volume":"19","author":"Kato","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"2025020409411137800_bib30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025020409411137800_bib31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ekir.2021.12.013","article-title":"The kidney protective effects of the sodium\u2013glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with chronic kidney disease treated with mineralocorticoid receptor antagonists","volume":"7","author":"Provenzano","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025020409411137800_bib32","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025020409411137800_bib33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/dom.13923","article-title":"The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis","volume":"22","author":"Scholtes","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2025020409411137800_bib34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ahj.2024.02.006","article-title":"Dapagliflozin and blood pressure in patients with chronic kidney disease and albuminuria","volume":"270","author":"Heerspink","year":"2024","journal-title":"Am Heart J"},{"key":"2025020409411137800_bib35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes","volume":"25","author":"Sugiyama","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"2025020409411137800_bib36","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.3390\/jcm9072243","article-title":"Nephroprotection by SGLT2 inhibition: back to the future?","volume":"9","author":"De Nicola","year":"2020","journal-title":"J Clin Med"},{"key":"2025020409411137800_bib37","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.kint.2024.05.006","article-title":"Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging","volume":"106","author":"Wada","year":"2024","journal-title":"Kidney Int"},{"key":"2025020409411137800_bib38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025020409411137800_bib39","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfad175","article-title":"Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis","volume":"39","author":"Caravaca-Font\u00e1n","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025020409411137800_bib40","doi-asserted-by":"publisher","first-page":"1242241","DOI":"10.3389\/fmed.2023.1242241","article-title":"Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy","volume":"10","author":"Dong","year":"2023","journal-title":"Front Med"},{"key":"2025020409411137800_bib41","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1093\/ndt\/gfac140","article-title":"High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database","volume":"38","author":"Fried","year":"2023","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae396\/60941200\/sfae396.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/1\/sfae396\/60941200\/sfae396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/1\/sfae396\/60941200\/sfae396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T09:41:19Z","timestamp":1738662079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae396\/7915991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae396","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,12,3]]},"article-number":"sfae396"}}